Take with water on an empty stomach or with a light meal. 800mg every 8 hours. Concomitant rifabutin: 1g indinavir every 8 hours and reduce rifabutin dose by ½. Hepatic insufficiency, or concomitant ketoconazole, itraconazole or delavirdine: 600mg indinavir every 8 hours.
Children's Dose for CRIXIVAN:
Not recommended. Take with water on an empty stomach or with a light meal. 3–18yrs: doses of 500mg/m2 every 8 hours have been used; see literature.
HIV protease inhibitor.
Concomitant alfuzosin, amiodarone, cisapride, lovastatin, simvastatin, oral midazolam, triazolam, alprazolam, pimozide, ergots, sildenafil (Revatio; only when used to treat PAH).
Maintain adequate hydration. Discontinue or suspend therapy during acute nephro- or urolithiasis. Impaired hepatic function. Monitor for hyperglycemia. Diabetes. Hemophilia (monitor for spontaneous bleeding). Asymptomatic severe leukocyturia: monitor urinalyses. Children (increased risk of nephro- or urolithiasis). Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
See Contraindications. Rifampin, St. John's wort, atazanavir, salmeterol, fluticasone (w. concomitant potent CYP3A4 inhibitor): not recommended. Caution with atorvastatin and rosuvastatin; titrate, use lowest necessary dose, and monitor. Potentiates PDE5 inhibitors, IV midazolam, trazodone, bosentan (reduce doses; see literature); antiarrhythmics, rifabutin, calcium channel blockers, clarithromycin, immunosuppressants, others metabolized by CYP3A4. Plasma levels increased by itraconazole, ketoconazole, delavirdine, CYP3A4 inhibitors. Plasma levels reduced by efavirenz, rifabutin, venlafaxine, phenobarbital, phenytoin, carbamazepine, other CYP3A4 inducers. Avoid concomitant colchicine if renal or hepatic impairment; otherwise: reduce dose: see literature. Separate dosing of indinavir and didanosine by at least 1 hour and give both on empty stomach.